AACE 2016:补充维生素D有望缓解糖尿病视网膜病变

2016-05-29 Seven L MedSci原创

研究者称,糖尿病视网膜病变患者与健康对照组相比,更有可能出现较低的25羟维生素D水平。纽约巴塞特医学中心医学系的Anawin Sanguankeo博士在AACE科学和临床会议上说:“维生素D可能在糖尿病视网膜病变的病理生理中起着一定的作用。在未来应该对维生素D能否预防糖尿病性视网膜病变或进展进行更多的研究。”他说,现在已知维生素D缺乏与一些心血管并发症有关,包括胰岛素分泌、代谢综合征和全身性糖尿病

研究者称,糖尿病视网膜病变患者与健康对照组相比,更有可能出现较低的25羟维生素D水平。

纽约巴塞特医学中心医学系的Anawin Sanguankeo博士在AACE科学和临床会议上说:“维生素D可能在糖尿病视网膜病变的病理生理中起着一定的作用。在未来应该对维生素D能否预防糖尿病性视网膜病变或进展进行更多的研究。”

他说,现在已知维生素D缺乏与一些心血管并发症有关,包括胰岛素分泌、代谢综合征和全身性糖尿病进展。在糖尿病视网膜病变的发病机制中,维生素D的作用仍然是一个争论的领域,但在大鼠模型中的研究表明两者间存在关联。

研究者们对11项观察性研究进行了系统回顾和荟萃分析,评估维生素D缺乏(血清25-(OH)D≤20 ng/mL)与糖尿病视网膜病变(n = 9,350)之间的关系。

荟萃分析数据显示,糖尿病视网膜病变与维生素D缺乏症之间存在关联(OR = 1.27; 95% CI, 1.17-1.37)。亚组分析显示,与健康对照组相比,糖尿病性视网膜病变患者有更低的血清25-(OH)D水平,平均相差–2.22 ng/mL(95% CI, –2.78 to –1.67)。

“我认为当前证据足够支持我们进一步的研究,”Sanguankeo说,“在未来应该对补充维生素D能都改善糖尿病性视网膜病变进行前瞻性的随机对照试验。”

原始出处:

Upala S, et al. Abstract #309. Presented at: The American Association for Clinical Endocrinologists Annual Scientific & Clinical Congress; May 25-29, 2016; Orlando, Fla.

Vitamin D deficiency may confer risk for retinopathy in diabetes
.Healio.May 28, 2016

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1655741, encodeId=93881655e416c, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Fri Feb 17 01:38:00 CST 2017, time=2017-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=127551, encodeId=805012e551ac, content=学习新知识了,感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160907/IMG57D00CF1965701770.jpg, createdBy=565c1948251, createdName=舒心和人, createdTime=Thu Sep 15 14:33:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1699189, encodeId=8796169918907, content=<a href='/topic/show?id=1349166054' target=_blank style='color:#2F92EE;'>#AACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1660, encryptionId=1349166054, topicName=AACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ca229920897, createdName=zgwhgch, createdTime=Sat Feb 25 04:38:00 CST 2017, time=2017-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88134, encodeId=6e098813428, content=好文章,得多学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Thu Jun 02 02:38:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269829, encodeId=d98812698295d, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Tue May 31 02:38:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413870, encodeId=0e6e14138e0e1, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Tue May 31 02:38:00 CST 2016, time=2016-05-31, status=1, ipAttribution=)]
    2017-02-17 shanyongle
  2. [GetPortalCommentsPageByObjectIdResponse(id=1655741, encodeId=93881655e416c, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Fri Feb 17 01:38:00 CST 2017, time=2017-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=127551, encodeId=805012e551ac, content=学习新知识了,感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160907/IMG57D00CF1965701770.jpg, createdBy=565c1948251, createdName=舒心和人, createdTime=Thu Sep 15 14:33:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1699189, encodeId=8796169918907, content=<a href='/topic/show?id=1349166054' target=_blank style='color:#2F92EE;'>#AACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1660, encryptionId=1349166054, topicName=AACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ca229920897, createdName=zgwhgch, createdTime=Sat Feb 25 04:38:00 CST 2017, time=2017-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88134, encodeId=6e098813428, content=好文章,得多学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Thu Jun 02 02:38:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269829, encodeId=d98812698295d, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Tue May 31 02:38:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413870, encodeId=0e6e14138e0e1, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Tue May 31 02:38:00 CST 2016, time=2016-05-31, status=1, ipAttribution=)]
    2016-09-15 舒心和人

    学习新知识了,感谢分享

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1655741, encodeId=93881655e416c, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Fri Feb 17 01:38:00 CST 2017, time=2017-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=127551, encodeId=805012e551ac, content=学习新知识了,感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160907/IMG57D00CF1965701770.jpg, createdBy=565c1948251, createdName=舒心和人, createdTime=Thu Sep 15 14:33:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1699189, encodeId=8796169918907, content=<a href='/topic/show?id=1349166054' target=_blank style='color:#2F92EE;'>#AACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1660, encryptionId=1349166054, topicName=AACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ca229920897, createdName=zgwhgch, createdTime=Sat Feb 25 04:38:00 CST 2017, time=2017-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88134, encodeId=6e098813428, content=好文章,得多学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Thu Jun 02 02:38:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269829, encodeId=d98812698295d, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Tue May 31 02:38:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413870, encodeId=0e6e14138e0e1, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Tue May 31 02:38:00 CST 2016, time=2016-05-31, status=1, ipAttribution=)]
    2017-02-25 zgwhgch
  4. [GetPortalCommentsPageByObjectIdResponse(id=1655741, encodeId=93881655e416c, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Fri Feb 17 01:38:00 CST 2017, time=2017-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=127551, encodeId=805012e551ac, content=学习新知识了,感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160907/IMG57D00CF1965701770.jpg, createdBy=565c1948251, createdName=舒心和人, createdTime=Thu Sep 15 14:33:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1699189, encodeId=8796169918907, content=<a href='/topic/show?id=1349166054' target=_blank style='color:#2F92EE;'>#AACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1660, encryptionId=1349166054, topicName=AACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ca229920897, createdName=zgwhgch, createdTime=Sat Feb 25 04:38:00 CST 2017, time=2017-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88134, encodeId=6e098813428, content=好文章,得多学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Thu Jun 02 02:38:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269829, encodeId=d98812698295d, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Tue May 31 02:38:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413870, encodeId=0e6e14138e0e1, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Tue May 31 02:38:00 CST 2016, time=2016-05-31, status=1, ipAttribution=)]
    2016-06-02 沉心多思

    好文章,得多学习了!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1655741, encodeId=93881655e416c, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Fri Feb 17 01:38:00 CST 2017, time=2017-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=127551, encodeId=805012e551ac, content=学习新知识了,感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160907/IMG57D00CF1965701770.jpg, createdBy=565c1948251, createdName=舒心和人, createdTime=Thu Sep 15 14:33:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1699189, encodeId=8796169918907, content=<a href='/topic/show?id=1349166054' target=_blank style='color:#2F92EE;'>#AACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1660, encryptionId=1349166054, topicName=AACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ca229920897, createdName=zgwhgch, createdTime=Sat Feb 25 04:38:00 CST 2017, time=2017-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88134, encodeId=6e098813428, content=好文章,得多学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Thu Jun 02 02:38:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269829, encodeId=d98812698295d, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Tue May 31 02:38:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413870, encodeId=0e6e14138e0e1, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Tue May 31 02:38:00 CST 2016, time=2016-05-31, status=1, ipAttribution=)]
    2016-05-31 zutt
  6. [GetPortalCommentsPageByObjectIdResponse(id=1655741, encodeId=93881655e416c, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Fri Feb 17 01:38:00 CST 2017, time=2017-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=127551, encodeId=805012e551ac, content=学习新知识了,感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160907/IMG57D00CF1965701770.jpg, createdBy=565c1948251, createdName=舒心和人, createdTime=Thu Sep 15 14:33:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1699189, encodeId=8796169918907, content=<a href='/topic/show?id=1349166054' target=_blank style='color:#2F92EE;'>#AACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1660, encryptionId=1349166054, topicName=AACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ca229920897, createdName=zgwhgch, createdTime=Sat Feb 25 04:38:00 CST 2017, time=2017-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88134, encodeId=6e098813428, content=好文章,得多学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Thu Jun 02 02:38:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269829, encodeId=d98812698295d, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Tue May 31 02:38:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413870, encodeId=0e6e14138e0e1, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Tue May 31 02:38:00 CST 2016, time=2016-05-31, status=1, ipAttribution=)]

相关资讯

PLOS ONE:提高维生素D水平可降低癌症风险

高维生素D水平可使癌症风险降低超过65%,该研究结果于4月6日发表在PLOS ONE。上述结果来自一项随机试验和一项前瞻性队列研究的汇合分析,较高的维生素D水平是指25-羟维生素D水平超过40ng/ml。“较高的25-羟维生素D浓度与包括乳腺癌、结肠癌、肺癌等在内的多种癌症风险降低有关。” 加州大学圣地亚哥分校医学院穆尔斯癌症中心公共卫生学博士Cedric Garland说道。“我和我的已故的哥哥

Pediatric Obesity:婴儿期补充维生素D可增加儿童3岁时的肌肉量

Pediatric Obesity:婴儿期补充维生素D可增加儿童3岁时的肌肉量目前对于维生素D对身体成分的影响尚未清楚。来自加拿大的一项研究探究了婴儿时期补充维生素D是否会影响儿童3 岁时的身体组分,其结果表明婴儿时期至3岁时高水平的维生素D可增加机体的肌肉量减少脂肪量,该研究成果已在线发表于Pediatric Obesity。采用随机双盲试验设计,共纳入了132名1月龄的健康婴儿,均为母乳喂养,

ARVO 2016:低水平的维生素D与非感染性葡萄膜炎的发生有关

ARVO 2016:低水平的维生素D与非感染性葡萄膜炎的发生有关在今年的视觉与眼科研究协会(AEVO)年会上展示的一项新的研究表明,与未患有非感染性葡萄膜炎的研究对象相比,非感染性葡萄膜炎患者的维生素D的水平较低。会议上,Lindsay Grotting博士说道,“鉴于非感染性葡萄膜炎是由免疫功能紊乱所致,本研究旨在确定维生素D的水平是否与其发生有关。”该项回顾性研究共纳入了53名非感染性葡萄膜炎

JACC:补充维生素D3可改善慢性心衰患者心功能(VINDICATE研究)

近年来维生素D已被誉为神奇的维生素,因为它其具有预防机体患慢性疾病如癌症、骨质疏松、心脏病,阿尔茨海默症等疾病的作用,促使民众保持身心健康。 英国研究人员进行的一项研究表明,日常补充维生素D有助于改善慢性心功能衰竭患者的身体状况。利兹大学的研究人员发现,维生素D3有助于改善慢性心力衰竭患者的心功能。研究结果在美国心脏病学会第65届年度科学会议上提出。 在他们的研究中,以Klaus Witte博士为

PLoS ONE:提高维生素D水平可有效预防癌症的发生

有研究显示增加人体血液中维生素D的含量可能成为一种预防癌症的重要手段,因为他们的研究发现随着维生素D水平的下降,癌症的发生率将大大提高。 PLos One杂志中,来自加州大学 - 圣地亚哥分校(UCSD)医学院的研究人员报道了他们是如何分析维生素D与癌症的联系,以确定什么样的血液维生素D水平对有效降低患癌症风险是必需的。 这项研究包括了除皮肤癌之外其他所有的恶性肿瘤。 该论文的作者之一,

Clin Nutr:低水平的维生素D与较高的身体脂肪百分比相关

最近的一项研究发现,没有心血管疾病的老年人,低水平的血清25羟维生素D与较高的身体脂肪百分比相关。荷兰鹿特丹大学医学中心的Anna Vitezova博士和同事分析了2158名45岁以上老年人的数据,平均年龄71岁,女性占66.7%。在1990-1993年对参与者进行家庭随访和基线测量,随访随访2-3年。在1997-1999年测量参与者的血清25羟维生素D浓度、身高、体重、腰围和腰围,在2002-2